Professor Zhijie Wei: Salvage Haplo-HCT Combined with Unrelated Cord Blood Infusion Improves Survival and Reduces aGVHD in Non-Remission AML Patients

Professor Zhijie Wei: Salvage Haplo-HCT Combined with Unrelated Cord Blood Infusion Improves Survival and Reduces aGVHD in Non-Remission AML Patients

The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held in Madrid, Spain, from June 13 to 16, 2024. The EHA conference featured numerous captivating presentations, particularly in the area of non-remission acute myeloid leukemia (NR-AML), which attracted significant attention. A study by Professor Zhijie Wei's team from Beijing Lu Daopei Hospital, targeting NR-AML patients undergoing salvage haploidentical hematopoietic stem cell transplantation (haplo-HCT) (Abstract No.: P1324), was included in the conference abstracts. This study aimed to retrospectively analyze clinical and follow-up data of NR-AML patients treated with haplo-HCT at the hospital, summarizing the impact of adding unrelated cord blood infusion on patient survival and the incidence of severe (grade III-IV) graft-versus-host disease (GVHD). To provide a deeper understanding of this study, Professor Zhijie Wei was invited to give a detailed introduction, which is summarized below.
Professor Jia Wei’s Team: Exceptional Efficacy of Dual-Targeted CD19/20 CAR-T Therapy in Treating Relapsed/Refractory B-Cell Lymphoma Patients

Professor Jia Wei’s Team: Exceptional Efficacy of Dual-Targeted CD19/20 CAR-T Therapy in Treating Relapsed/Refractory B-Cell Lymphoma Patients

The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held in Madrid, Spain, from June 13 to 16, 2024. As the largest international conference in the field of hematology in Europe, it annually attracts experts and scholars from around the world to share and discuss innovative ideas and the latest scientific and clinical research findings in hematology. At this year's conference, several studies from Professor Jia Wei's team at Tongji Hospital, Huazhong University of Science and Technology, were selected for poster or electronic poster presentations. This report highlights two studies in the field of aggressive B-cell lymphoma (P2090 and P1164), aiming to provide references for improving the long-term survival and optimizing treatment options for relapsed/refractory B-cell lymphoma.
EHA Expert Interview with Professor Yang Liang: Immune-Based Insights into Secondary Resistance to Anti-CD38 Therapy in Multiple Myeloma

EHA Expert Interview with Professor Yang Liang: Immune-Based Insights into Secondary Resistance to Anti-CD38 Therapy in Multiple Myeloma

The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13 to 16, 2024, in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world to share and discuss innovative ideas and the latest scientific and clinical research findings in hematology. At this year's conference, a study by Professor Yang Liang's team from Sun Yat-sen University Cancer Center on "Bone Marrow Ecosystem Formation and Secondary Resistance to Anti-CD38 Therapy in Multiple Myeloma" was selected for an oral presentation (S198). This study provides significant insights and references for optimizing resistance management in anti-CD38 therapy for multiple myeloma. We invited Professor Yang Liang for an interview to delve into the study's content and its clinical implications, as well as to highlight future research directions in this field.
EHA China Voice丨Professor Liang Wang’s Team: Exploring Optimal Treatment for Vitreoretinal Lymphoma

EHA China Voice丨Professor Liang Wang’s Team: Exploring Optimal Treatment for Vitreoretinal Lymphoma

The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held from June 13 to 16, 2024, in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world every year to share and discuss innovative ideas and the latest scientific and clinical research results in hematology. At this year's conference, a study by Professor Liang Wang's team from Beijing Tongren Hospital, Capital Medical University, was selected for poster presentation (P1187). The study, based on a PRISMA-compliant meta-analysis and systematic review, explored the best treatment options for vitreoretinal lymphoma (VRL). To provide a better understanding of the research findings, "Oncology Frontier - Hematology Frontier" invited the first author of the study, Dr.  Jing Gao, to introduce the research in detail and Professor Liang Wang to provide an in-depth commentary.
Prof. Yue Lu’s Team Compares ATG-T vs. ATLG in TBI-Based Conditioning for Alternative Donor Allogeneic Hematopoietic Stem Cell Transplantation

Prof. Yue Lu’s Team Compares ATG-T vs. ATLG in TBI-Based Conditioning for Alternative Donor Allogeneic Hematopoietic Stem Cell Transplantation

The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13 to 16, 2024, in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world each year to share and discuss innovative ideas and the latest scientific and clinical research findings in hematology. At this year's conference, a study by Dr. Fang Xu from Prof. Yue Lu's team at Beijing Lu Daopei Hospital was selected for poster presentation (P1299). The study compared the application of ATG-T vs. ATLG in TBI-based conditioning for alternative donor allogeneic hematopoietic stem cell transplantation. We invited Dr. Fang Xu to introduce the study and provide insights for clinical practice or future research.
EHA-CSH Joint Symposium: Professor Jianxiang Wang on Sino-European Hematology Exchange and Future Development

EHA-CSH Joint Symposium: Professor Jianxiang Wang on Sino-European Hematology Exchange and Future Development

The 29th Annual Congress of the European Hematology Association (EHA) took place from June 13 to 16, 2024, in Madrid, Spain. Renowned as the "Olympics" of European hematology, the EHA Congress is celebrated for its cutting-edge scientific discussions and extensive clinical research findings, drawing global attention. Among the numerous highlights of this year's event was the EHA-CSH Joint Symposium, which brought together leading experts from China and Europe to discuss the latest advancements in T-cell acute lymphoblastic leukemia (T-ALL). Oncology Frontier – Hematology Frontier had the privilege of interviewing Professor Jianxiang Wang, co-chair of the symposium and Chief Clinical Expert at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to share his insights on the event, key highlights of the EHA-CSH symposium, and his own research presentations and future directions.
EASL Expert Interview | Professor Fengmin Lu: From Mechanistic Research to Clinical Cure – Exploring Potential Treatment Strategies for CHB

EASL Expert Interview | Professor Fengmin Lu: From Mechanistic Research to Clinical Cure – Exploring Potential Treatment Strategies for CHB

In the field of chronic HBV infection, the discovery of basic core promoter (BCP) and pre-core (PC) mutations dates back nearly thirty years. However, the potential link between these mutations and the progression of chronic hepatitis B (CHB), as well as their impact on antiviral treatment response, has been a focal point for virologists for a long time. At the 2024 European Association for the Study of the Liver (EASL) Annual Meeting, Professor Fengmin Lu from the Peking University Center for Infectious Diseases shared his team’s latest research findings. Firstly, they revealed the impact of BCP+PC mutant virus infection on hepatocytes, indicating that this mutant virus induces more extensive and severe hepatocyte degeneration and cytoplasmic vacuolization, and suppresses the endogenous IFN-α/γ signaling pathway in human hepatocytes. This discovery may offer a new explanation for the poor response to interferon therapy in some patients. Additionally, Professor Lu delved into the regulation and secretion mechanisms of HBsAg expression in integrated HBV DNA, proposing new strategies for CHB treatment based on these findings. We had an in-depth interview with Professor Lu, and the content is organized here for our readers.
EASL Five-Minute Briefing: Professor Jian Gao Fan Reviews Cutting-Edge Progress in MAFLD Drug Development

EASL Five-Minute Briefing: Professor Jian Gao Fan Reviews Cutting-Edge Progress in MAFLD Drug Development

On June 8, the European Association for the Study of the Liver (EASL) Annual Meeting concluded successfully in Milan, Italy. This conference brought together top experts and scholars from around the world to discuss the latest technologies and future trends in liver disease treatment. Among the key topics was the development of new drugs for metabolic-associated fatty liver disease (MAFLD). Professor Jian Gao Fan, Director of the Gastroenterology Department at Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, shared insights on the current state and cutting-edge progress in MAFLD drug development.
EHA Expert Interview with Professor Zhihui Li: Safe and Effective Use of Luspatercept Post-Allo-HSCT in Patients with Hematologic Malignancies

EHA Expert Interview with Professor Zhihui Li: Safe and Effective Use of Luspatercept Post-Allo-HSCT in Patients with Hematologic Malignancies

The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13 to 16, 2024, in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world to share and discuss innovative ideas and the latest scientific and clinical research findings in hematology. At this year's conference, Professor Zhihui Li from Beijing GoBroad Boren Hospital presented research on the "Safety and Efficacy of Luspatercept in Allogeneic Transplantation for Malignant Hematologic Diseases." This study provides valuable insights for clinical practice. Oncology Frontier - Hematology Frontier had the opportunity to interview Dr. Zhihui Li at the conference to delve into the study's findings and their clinical implications.
EHA China’s Voice | Breakthrough Studies from Professor Huilai Zhang’s Team Unveiled at the EHA Annual Meeting – Deciphering the Genetic Secrets and New Treatment Strategies for Follicular Lymphoma

EHA China’s Voice | Breakthrough Studies from Professor Huilai Zhang’s Team Unveiled at the EHA Annual Meeting – Deciphering the Genetic Secrets and New Treatment Strategies for Follicular Lymphoma

The 29th European Hematology Association (EHA) Annual Meeting took place from June 13-16, 2024, in Madrid, Spain. At this prestigious event, Professor Huilai Zhang's team from Tianjin Medical University Cancer Institute and Hospital presented several research studies in poster sessions, highlighting the clinical features, genetic variations, and histological grading of follicular lymphoma. Their work offers a deeper understanding of the disease. Additionally, Professor Zhang's team delved into the epidemiological characteristics and prognosis of primary gastrointestinal follicular lymphoma, providing new insights for diagnosing and treating this rare disease. In the field of mantle cell lymphoma (MCL) treatment, their study on the Orelabrutinib-Lenalidomide-Rituximab regimen brings new hope to patients. Of particular note is their research on the impact of CD58 genetic alterations in diffuse large B-cell lymphoma (DLBCL), which enhances our understanding of the tumor immune microenvironment and suggests new approaches for personalized treatment. To provide a comprehensive overview of these research findings,Oncology Frontier - Hematology Frontier invited Professor Huilai Zhang to share the details.